Methods of treating complement mediated diseases with fusion protein constructs comprising anti-C3d antibody and a complement modulator

US11879008B2 · kind B2 · utility

Assignee

• Q32 Bio Inc. · US

Inventors

• Michael Steven Curtis · Waltham, US
• Michael Storek · Cambridge, US
• Shelia M. Violette · Lexington, US
• Susan L. Kalled · Concord, US
• Kelly C. Fahnoe · Waltham, US
• Cheng Ran Huang · Belmont, US
• Ellen Garber Stark · Cambridge, US
• Frederick R. Taylor · Milton, US
• Justin Andrew Caravella · Cambridge, US
• Vernon Michael Holers · Denver, US

Key dates

• Filing date: Jun 4, 2021
• Grant date: Jan 23, 2024
• Expiry date: Jun 4, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are fusion protein constructs that can bind a complement-associated antigen, comprising a targeting moiety and a complement modulator protein, or a fragment thereof or a variant thereof. The targeting moiety is an antibody or an antigen binding fragment thereof, in some examples. Further provided are methods of using the fusion protein constructs, for example, in treating complement mediation conditions.